Exercise and Muscle Preservation During GLP-1 Treatment

What science says about GLP-1 and body composition

Clinical studies with GLP-1 agonists show that weight loss without exercise accompaniment results in approximately 60 to 70 percent fat and 30 to 40 percent lean mass. That means out of every 10 kilos lost, somewhere between 3 and 4 could be muscle.

When resistance exercise enters the equation, the ratio changes. Research shows that people who combine the medication with regular strength training manage to reverse this ratio to around 80 to 85 percent fat and 15 to 20 percent lean mass. The difference is significant.

ACSM and AHA recommend at least 150 minutes of aerobic activity per week, combined with two to three strength training sessions. These guidelines are even more important for people going through weight loss with medication.

Types of exercise that make a difference

Resistance training is what most impacts lean mass preservation. When you lift weights, you create a stimulus that tells your body: I need to keep this muscle. Even in a caloric deficit, well-structured strength training can not only preserve but even increase lean mass in some situations.

Aerobic exercise has its place too. It burns calories, improves cardiovascular health, aids recovery, and contributes to the caloric deficit needed to lose fat. But done in isolation, without resistance, it does not protect muscle.

The ideal is to combine both. A realistic routine could be: three strength training sessions per week, 30 to 45 minutes each, focusing on the major muscle groups. Add 20 to 30 minutes of moderate cardio on alternate days or after the strength session.

Exercise timing in relation to dose

If you inject once a week, you may notice that in the days following the injection, especially the first 24 to 72 hours, your appetite increases and your energy may decrease. This is the period when the medication concentration is rising.

Some people prefer to train in the days right after their injection, when the appetite reduction effect is most present and it is easier to control diet. Others prefer to train a little before the next dose, when energy is more stable.

What matters most is observing your own pattern and adjusting. PeptPro lets you log when you train and how you feel, which makes it easier to identify the timing that works best for you.

Mistakes you can avoid

The first common mistake is focusing only on cardio and neglecting strength training. Running, cycling, group classes are great for burning calories, but they do not offer the stimulus needed to preserve muscle. If you only do cardio and are in a caloric deficit, you are losing lean mass along with fat.

The second mistake is not eating enough protein. During weight loss, protein needs increase, not decrease. The general recommendation is 1.2 to 1.6 grams of protein per kilogram of body weight per day for people going through weight loss with exercise. A 70-kilogram woman needs approximately 85 to 110 grams of protein per day.

The third mistake is training too hard at the start. When you are in the early phase of treatment and still adapting to the medication, your body is already going through changes. Adding too much intense exercise can lead to injuries, exhaustion, or simply abandonment. Start with a moderate routine and build gradually.

How to track progress

The scale does not tell the whole story. When you are gaining muscle and losing fat at the same time, the number on the display may change little or even go up slightly. That does not mean things are going badly. It means the composition is changing.

Circumference measurements, photos taken under the same conditions every two to four weeks, and strength tests are more honest ways to track what is happening.

Bioimpedance tests, when available, give a reading of the ratio between lean mass and fat. If you have access to this kind of assessment at your gym or doctor's office, use it as a reference over the months.

PeptPro organizes your weight, hydration, and progress data so you have clarity on what is happening. Download here.

References

• EMA — Mounjaro (tirzepatida), EPAR
• Jastreboff et al., SURMOUNT-1 — NEJM (2022)
• OMS — Obesity and overweight, fact sheet